EARLENS CORPORATION – Trademark Portfolio

Entity Type: 03

EARLENS CORPORATION holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 10 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include EARLENS and VIRSONO HEARING CENTER. The owner is based in Menlo Park, CA.

4045-A Campbell Ave

Menlo Park, CA 94025

12 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

EARLENS CORPORATION's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (10 filings)

Surgical, medical, dental and veterinary apparatus and instruments

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does EARLENS CORPORATION have?

EARLENS CORPORATION has 12 U.S. trademarks filed with the USPTO. Of these, 6 registered, 3 abandoned, 3 cancelled.

What trademark classes does EARLENS CORPORATION file in?

EARLENS CORPORATION files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are EARLENS CORPORATION's most well-known trademarks?

EARLENS CORPORATION's registered trademark portfolio includes well-known marks such as EARLENS and VIRSONO HEARING CENTER. These are among 6 currently registered trademarks in the portfolio.

What is EARLENS CORPORATION's trademark registration success rate?

EARLENS CORPORATION has a 50% trademark registration rate, with 6 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.